Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies
Authors:
- Elisabetta XueEXElisabetta Xue
- Dara Bracken-ClarkeDBDara Bracken-Clarke
- Harris KrauseHKHarris Krause
- Tolulope AdeyeluTATolulope Adeyelu
- Mark G. EvansMEMark G. Evans
- Dilara AkbulutDADilara Akbulut
- Martha QuezadoMQMartha Quezado
- Nishant GandhiNGNishant Gandhi
- Alex FarrellAFAlex Farrell
- Heloisa P. SoaresHSHeloisa P. Soares
- Emil LouELEmil Lou
- Minh PhanMPMinh Phan
Open Access
Abstract
Olfactory neuroblastoma (ONB), sinonasal undifferentiated carcinoma (SNUC), and sinonasal neuroendocrine carcinoma (SNEC) are rare malignancies arising from the sinonasal tract with limited therapeutic options. The expression of the somatostatin receptor 2 gene (SSTR2), which is expressed in other neuroendocrine neoplasms and is therapeutically actionable, has been reported in these tumors. Here, we analyzed SSTR2 gene expression and its associations with genomic features, established biomarkers predicting of immune response, and the tumor immune microenvironment in a cohort of ONB, SNUC, and SNEC tumor samples (26, 13, and 8 samples, respectively) from a real-world database. SSTR2 gene expression was high in neural-type ONB and low in basal-type ONB and in most of the SNUC and SNEC cases; there was no difference in expression between primary and metastatic tumors. The T cell-inflamed (TCI) score analysis classified 38.5% of SNUC cases as T cell-inflamed compared to only 3.9% of ONB and 0% of SNEC cases; 26.9% of ONB cases were classified as intermediate TCI; and SNEC had the lowest relative immune cell infiltration by deconvolution. In high SSTR2-expressing ONB, there was a higher proportion of infiltrating of Natural Killer cells and dendritic cells by deconvolution. Additionally, high SSTR2-expressing ONB was enriched for proliferation pathways, including E2F and Myc targets and G2M checkpoints. In conclusion, our findings delineate significant differences between these three types of sinonasal malignancies that were examined. In ONB, relative to SNUC and SNEC, the SSTR2 expression profile, combined with its immune profiles, indicates potential novel therapeutic strategies and combinations for this unmet clinical need. Conversely, the inflammatory microenvironment of SNUC may be targetable using immuno-oncologic therapies.Keywords
This publication has 49 references indexed in Scilit:
- Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancerCancer Cell, 2024
- Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastomaEuropean Journal of Cancer, 2021
- SSTR2 Expression in Olfactory Neuroblastoma: Clinical and Therapeutic ImplicationsHead and Neck Pathology, 2021
- The value of 68Gallium‐DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case seriesHead & Neck, 2021
- A subset of sinonasal undifferentiated carcinoma is associated with transcriptionally active high-risk human papillomavirus by in situ hybridization: a clinical and pathologic analysisHuman Pathology, 2020
- Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell OntogenyCell Reports, 2018
- Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive featureHuman Pathology, 2018
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell linesCancer Chemotherapy and Pharmacology, 2015
- Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?European Journal of Nuclear Medicine and Molecular Imaging, 2007